アブストラクト
| Title | 産科大量出血の病態と止血目的の輸血治療 |
|---|---|
| Subtitle | 第123回学術集会発表論文 教育講演 |
| Authors | 山本晃士* |
| Authors (kana) | |
| Organization | *埼玉医科大学総合医療センター輸血細胞医療部 |
| Journal | 分娩と麻酔 |
| Volume | |
| Number | 102 |
| Page | 55-65 |
| Year/Month | 2020 / 11 |
| Article | 報告 |
| Publisher | 日本産科麻酔学会 |
| Abstract | 「はじめに」わが国の妊産婦死亡の最多原因は現在でも大量出血であるが, その半数以上は, 適切な輸血治療がなされていれば救命できた可能性が高いと指摘されている. 産科大量出血の特徴は, 「予測困難なケースが多い」ことと, 胎盤剥離部など "面からの出血" が起こるので「短時間で出血量が一気に増えて危機的大量出血に至る」ことである. また従来, その輸血治療は, 止血するまで赤血球や新鮮凍結血漿をやみくもに投与するという非科学的な手法に終始してきた. 本稿では, 産科大量出血の背景にある病態を明解に述べるとともに, その際に行うべき止血目的の輸血治療についてエビデンスに基づいて概説する. 「1. 産科大量出血の原因と特徴」産科大量出血の原因は, 前置胎盤, 癒着胎盤, 胎盤早期剥離, 弛緩出血, 産道裂傷, 子宮破裂, 産科播種性血管内凝固(disseminated intravascular coagulation: DIC)の合併など多岐にわたるが, 原疾患によって止血法や輸血治療も異なるため, 迅速な鑑別が肝要である. |
| Practice | 臨床医学：一般 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Al-Zirqi I, Vangen S, Forsen L, et al. Prevalence and risk factors of severe obstetric haemorrhage. BJOG 2008 ; 115 : 1265-72.
- 2) McLintock C James AH. Obstetric hemorrhage. J Thromb Haemost 2011 ; 9 : 1441-51.
- 3) Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev 2009 ; 23 : 167-76.
- 4) Hiippala, ST, Myllyla GJ, Vahtera EM. Hemosta-tic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995 ; 81 : 360-5.
- 5) Velik-Salchner C, Haas T, Innerhofer P, et al. The effect of fibrinogen concentrate on thrombocy-topenia. J Thromb Haemost 2007 ; 5 : 1019-25.
残りの26件を表示する
- 6) Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis : a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012 ; 114 : 261-74.
- 7) Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding : a review of critical levels and replacement therapy. Transfu-sion 2014 ; 54 : 1389-405.
- 8) Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007 ; 5 : 266-73.
- 9) Rand MD, Lock JB, van't Veer C, et al. Blood clotting in minimally altered whole blood. Blood 1996 ; 88 : 3432-45.
- 10) Segal JB, Dizk WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures : an evidence-based review. Transfusion 2005 ; 45 : 1413-25.
- 11) Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders : revisited using global coagulation/anticoagulation testing. Br J Haematol 2009 ; 147 : 77-82.
- 12) Meybohm P, Zacharowski K, Weber CF. Point-of-care coagulation management in intensive care medicine. Crit Care 2013 ; 17 : 218.
- 13) Johansson PI, Stensballe J, Oliveri R, et al. How I treat patients with massive hemorrhage. Blood 2014 ; 124 : 3052-8.
- 14) Weber CF, Gorlinger K, Meininger D, et al. Point-of-care testing : a prospective, randomized clinic-al trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012 ; 117 : 531-47.
- 15) Collins PW, Solomon C, Sutor K, et al. Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate. Br J Anaesth 2014 ; 113 : 585-95.
- 16) Chowdary P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory para-meters of haemostasis in critically ill patients. Br J Haematol 2004 ; 125 : 69-73.
- 17) 大石晃嗣, 松本剛史, 田中由美ほか. クリオプレシピテート院内作製プロトコール. 日本輸血細胞治療学会誌 2016 ; 62 : 664-72.
- 18) Rahe-Meyer N, Sorensen B. Fibrinogen concen-trate for management of bleeding. J Thromb Haemost 2011 ; 9 : 1-5.
- 19) O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004 ; 126 : 11-28.
- 20) Bell SF, Rayment R, Collins PW, et al. The use of fibrinogen concentrate to correct hypofibri-nogenaemia rapidly during obstetric haemor-rhage. Int J Obstet Anesth 2010 ; 19 : 218-23.
- 21) Glover NJ, Collis RE, Collins P. Fibrinogen concentrate use during major obstetric haemor-rhage. Anaesthesia 2010 ; 65 : 1229-30.
- 22) 岩尾憲明, 須波 玲, 大森真紀子ほか. 産科大量出血に対するクリオプレシピテートの有用性. 日本輸血細胞治療学会誌 2012 ; 58 : 486-91.
- 23) Kikuchi M, Itakura A, Miki A, et al. Fibrinogen concentrate substitution therapy for obstetric hemorrhage complicated by coagulopathy. J Obstet Gynaecol Res 2013 ; 39 : 770-6.
- 24) Matsunaga S, Takai Y, Nakamura E, et al. The clinical efficacy of fibrinogen concentrate in massive obstetric hemorrhage with hypofibri-nogenemia. Sci Rep 2017 ; 7 : 46749.
- 25) Lang T, Johanning K, Metzler H, et al. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 2009 ; 108 : 751-8.
- 26) Simonazzi G, Bisulli M, Saccone G, et al. Tranex-amic acid for preventing postpartum blood loss after cesarean delivery : a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand 2016 ; 95 : 28-37.
- 27) Bolliger D, Gorlinger K, Tanaka KA. Pathophy-siology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010 ; 113 : 1205-19.
- 28) Hethershaw EL, Cilia La Corte AL, Duval C, et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost 2014 ; 12 : 197-205.
- 29) Kurniawan NA, Grimbergen J, Koopman J, et al. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost 2014 ; 12 : 1687-96.
- 30) Franchini M, Franchi M, Bergamini V, et al. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost 2008 ; 34 : 104-12.
- 31) 小林隆夫. 産科領域の大量出血と輸血療法. 医学のあゆみ「周術期輸血医療 UPDATE」 2008 ; 224 : 221-6.
